nodes	percent_of_prediction	percent_of_DWPC	metapath
Podofilox—Etoposide—uterine cancer	0.482	1	CrCtD
Podofilox—Teniposide—Etoposide—uterine cancer	0.276	1	CrCrCtD
Podofilox—NR3C1—Medroxyprogesterone Acetate—uterine cancer	0.0523	0.271	CbGbCtD
Podofilox—TOP2A—Epirubicin—uterine cancer	0.0347	0.18	CbGbCtD
Podofilox—NR3C1—Progesterone—uterine cancer	0.0347	0.18	CbGbCtD
Podofilox—TOP2A—Etoposide—uterine cancer	0.027	0.14	CbGbCtD
Podofilox—TOP2A—Doxorubicin—uterine cancer	0.0184	0.0955	CbGbCtD
Podofilox—CYP2C19—Progesterone—uterine cancer	0.01	0.0519	CbGbCtD
Podofilox—CYP3A4—Medroxyprogesterone Acetate—uterine cancer	0.0073	0.0379	CbGbCtD
Podofilox—CYP3A4—Progesterone—uterine cancer	0.00484	0.0251	CbGbCtD
Podofilox—CYP3A4—Etoposide—uterine cancer	0.00216	0.0112	CbGbCtD
Podofilox—CYP3A4—Doxorubicin—uterine cancer	0.00148	0.00765	CbGbCtD
Podofilox—Skin papilloma—Progesterone—uterine cancer	0.0013	0.0822	CcSEcCtD
Podofilox—TUBA4A—myometrium—uterine cancer	0.000889	0.0461	CbGeAlD
Podofilox—TUBA4A—epithelium—uterine cancer	0.000698	0.0362	CbGeAlD
Podofilox—TUBA4A—uterine cervix—uterine cancer	0.000692	0.0359	CbGeAlD
Podofilox—TUBA4A—smooth muscle tissue—uterine cancer	0.000672	0.0349	CbGeAlD
Podofilox—TUBA4A—decidua—uterine cancer	0.000659	0.0342	CbGeAlD
Podofilox—TOP2A—myometrium—uterine cancer	0.000658	0.0341	CbGeAlD
Podofilox—TUBB—myometrium—uterine cancer	0.000652	0.0338	CbGeAlD
Podofilox—TUBA4A—renal system—uterine cancer	0.000647	0.0336	CbGeAlD
Podofilox—Redness—Progesterone—uterine cancer	0.000628	0.0397	CcSEcCtD
Podofilox—TUBA4A—endometrium—uterine cancer	0.000626	0.0325	CbGeAlD
Podofilox—TUBA4A—mammalian vulva—uterine cancer	0.000605	0.0314	CbGeAlD
Podofilox—TUBA4A—uterus—uterine cancer	0.000577	0.0299	CbGeAlD
Podofilox—TUBA4A—female reproductive system—uterine cancer	0.000518	0.0269	CbGeAlD
Podofilox—TOP2A—uterine cervix—uterine cancer	0.000512	0.0266	CbGeAlD
Podofilox—TUBB—uterine cervix—uterine cancer	0.000507	0.0263	CbGeAlD
Podofilox—TUBB—smooth muscle tissue—uterine cancer	0.000493	0.0256	CbGeAlD
Podofilox—TOP2A—decidua—uterine cancer	0.000488	0.0253	CbGeAlD
Podofilox—Tenderness—Progesterone—uterine cancer	0.000486	0.0307	CcSEcCtD
Podofilox—TUBB—decidua—uterine cancer	0.000483	0.0251	CbGeAlD
Podofilox—TUBA4A—female gonad—uterine cancer	0.000472	0.0245	CbGeAlD
Podofilox—Skin discolouration—Progesterone—uterine cancer	0.000469	0.0297	CcSEcCtD
Podofilox—TUBA4A—vagina—uterine cancer	0.000469	0.0243	CbGeAlD
Podofilox—TOP2A—endometrium—uterine cancer	0.000463	0.024	CbGeAlD
Podofilox—TUBB—endometrium—uterine cancer	0.000459	0.0238	CbGeAlD
Podofilox—TOP2A—mammalian vulva—uterine cancer	0.000448	0.0232	CbGeAlD
Podofilox—TUBB—mammalian vulva—uterine cancer	0.000444	0.023	CbGeAlD
Podofilox—Tenderness—Medroxyprogesterone Acetate—uterine cancer	0.00044	0.0278	CcSEcCtD
Podofilox—TOP2A—uterus—uterine cancer	0.000426	0.0221	CbGeAlD
Podofilox—TUBB—uterus—uterine cancer	0.000423	0.0219	CbGeAlD
Podofilox—Ulcer—Medroxyprogesterone Acetate—uterine cancer	0.000406	0.0257	CcSEcCtD
Podofilox—TOP2A—female gonad—uterine cancer	0.000349	0.0181	CbGeAlD
Podofilox—Swelling—Progesterone—uterine cancer	0.000349	0.022	CcSEcCtD
Podofilox—TOP2A—vagina—uterine cancer	0.000347	0.018	CbGeAlD
Podofilox—TUBB—female gonad—uterine cancer	0.000346	0.0179	CbGeAlD
Podofilox—TUBB—vagina—uterine cancer	0.000344	0.0178	CbGeAlD
Podofilox—Ulcer—Dactinomycin—uterine cancer	0.000317	0.02	CcSEcCtD
Podofilox—Swelling—Medroxyprogesterone Acetate—uterine cancer	0.000316	0.02	CcSEcCtD
Podofilox—TUBA4A—lymph node—uterine cancer	0.000303	0.0157	CbGeAlD
Podofilox—NR3C1—myometrium—uterine cancer	0.000302	0.0157	CbGeAlD
Podofilox—Tingling sensation—Etoposide—uterine cancer	0.00027	0.0171	CcSEcCtD
Podofilox—Dry skin—Medroxyprogesterone Acetate—uterine cancer	0.000256	0.0162	CcSEcCtD
Podofilox—Pain—Carboplatin—uterine cancer	0.000246	0.0156	CcSEcCtD
Podofilox—Skin discolouration—Etoposide—uterine cancer	0.00024	0.0152	CcSEcCtD
Podofilox—NR3C1—epithelium—uterine cancer	0.000237	0.0123	CbGeAlD
Podofilox—NR3C1—uterine cervix—uterine cancer	0.000235	0.0122	CbGeAlD
Podofilox—Ulcer—Etoposide—uterine cancer	0.000229	0.0145	CcSEcCtD
Podofilox—NR3C1—smooth muscle tissue—uterine cancer	0.000228	0.0118	CbGeAlD
Podofilox—TOP2A—lymph node—uterine cancer	0.000224	0.0116	CbGeAlD
Podofilox—NR3C1—decidua—uterine cancer	0.000224	0.0116	CbGeAlD
Podofilox—Inflammation—Etoposide—uterine cancer	0.000224	0.0141	CcSEcCtD
Podofilox—TUBB—lymph node—uterine cancer	0.000222	0.0115	CbGeAlD
Podofilox—NR3C1—renal system—uterine cancer	0.00022	0.0114	CbGeAlD
Podofilox—Haemoglobin—Progesterone—uterine cancer	0.000214	0.0135	CcSEcCtD
Podofilox—Haemorrhage—Progesterone—uterine cancer	0.000213	0.0135	CcSEcCtD
Podofilox—NR3C1—endometrium—uterine cancer	0.000213	0.011	CbGeAlD
Podofilox—Skin exfoliation—Etoposide—uterine cancer	0.000207	0.0131	CcSEcCtD
Podofilox—NR3C1—mammalian vulva—uterine cancer	0.000206	0.0107	CbGeAlD
Podofilox—CYP2C19—vagina—uterine cancer	0.000204	0.0106	CbGeAlD
Podofilox—NR3C1—uterus—uterine cancer	0.000196	0.0102	CbGeAlD
Podofilox—Haemoglobin—Medroxyprogesterone Acetate—uterine cancer	0.000194	0.0123	CcSEcCtD
Podofilox—Haemorrhage—Medroxyprogesterone Acetate—uterine cancer	0.000193	0.0122	CcSEcCtD
Podofilox—Immune system disorder—Progesterone—uterine cancer	0.000192	0.0122	CcSEcCtD
Podofilox—Erythema—Progesterone—uterine cancer	0.000185	0.0117	CcSEcCtD
Podofilox—Redness—Epirubicin—uterine cancer	0.00018	0.0114	CcSEcCtD
Podofilox—Swelling—Etoposide—uterine cancer	0.000178	0.0113	CcSEcCtD
Podofilox—TOP2A—Teniposide—Etoposide—uterine cancer	0.000176	0.157	CbGdCrCtD
Podofilox—NR3C1—female reproductive system—uterine cancer	0.000176	0.00913	CbGeAlD
Podofilox—Immune system disorder—Medroxyprogesterone Acetate—uterine cancer	0.000174	0.011	CcSEcCtD
Podofilox—Blister—Epirubicin—uterine cancer	0.000169	0.0107	CcSEcCtD
Podofilox—Erythema—Medroxyprogesterone Acetate—uterine cancer	0.000168	0.0106	CcSEcCtD
Podofilox—Redness—Doxorubicin—uterine cancer	0.000167	0.0105	CcSEcCtD
Podofilox—CYP3A4—renal system—uterine cancer	0.000166	0.00863	CbGeAlD
Podofilox—NR3C1—female gonad—uterine cancer	0.00016	0.00831	CbGeAlD
Podofilox—NR3C1—vagina—uterine cancer	0.000159	0.00826	CbGeAlD
Podofilox—Unspecified disorder of skin and subcutaneous tissue—Progesterone—uterine cancer	0.000157	0.0099	CcSEcCtD
Podofilox—Skin ulcer—Epirubicin—uterine cancer	0.000156	0.00987	CcSEcCtD
Podofilox—Blister—Doxorubicin—uterine cancer	0.000156	0.00986	CcSEcCtD
Podofilox—Oedema—Progesterone—uterine cancer	0.000151	0.00956	CcSEcCtD
Podofilox—Stinging—Epirubicin—uterine cancer	0.00015	0.00948	CcSEcCtD
Podofilox—Skin disorder—Progesterone—uterine cancer	0.000147	0.00929	CcSEcCtD
Podofilox—Skin ulcer—Doxorubicin—uterine cancer	0.000144	0.00913	CcSEcCtD
Podofilox—TOP2A—Methyltestosterone—Medroxyprogesterone Acetate—uterine cancer	0.000144	0.128	CbGdCrCtD
Podofilox—Unspecified disorder of skin and subcutaneous tissue—Medroxyprogesterone Acetate—uterine cancer	0.000142	0.00897	CcSEcCtD
Podofilox—Stinging—Doxorubicin—uterine cancer	0.000139	0.00878	CcSEcCtD
Podofilox—Oedema—Medroxyprogesterone Acetate—uterine cancer	0.000137	0.00866	CcSEcCtD
Podofilox—Insomnia—Progesterone—uterine cancer	0.000137	0.00865	CcSEcCtD
Podofilox—Paraesthesia—Progesterone—uterine cancer	0.000136	0.00858	CcSEcCtD
Podofilox—Skin discolouration—Epirubicin—uterine cancer	0.000135	0.00851	CcSEcCtD
Podofilox—Skin disorder—Medroxyprogesterone Acetate—uterine cancer	0.000133	0.00841	CcSEcCtD
Podofilox—CYP3A4—female reproductive system—uterine cancer	0.000133	0.00691	CbGeAlD
Podofilox—Erythema—Dactinomycin—uterine cancer	0.000131	0.00828	CcSEcCtD
Podofilox—Pain—Progesterone—uterine cancer	0.000129	0.00818	CcSEcCtD
Podofilox—Ulcer—Epirubicin—uterine cancer	0.000129	0.00812	CcSEcCtD
Podofilox—TOP2A—Methyltestosterone—Progesterone—uterine cancer	0.000126	0.112	CbGdCrCtD
Podofilox—Inflammation—Epirubicin—uterine cancer	0.000125	0.00792	CcSEcCtD
Podofilox—Skin discolouration—Doxorubicin—uterine cancer	0.000125	0.00787	CcSEcCtD
Podofilox—Insomnia—Medroxyprogesterone Acetate—uterine cancer	0.000124	0.00784	CcSEcCtD
Podofilox—Paraesthesia—Medroxyprogesterone Acetate—uterine cancer	0.000123	0.00778	CcSEcCtD
Podofilox—Ulcer—Doxorubicin—uterine cancer	0.000119	0.00752	CcSEcCtD
Podofilox—Skin exfoliation—Epirubicin—uterine cancer	0.000116	0.00734	CcSEcCtD
Podofilox—Inflammation—Doxorubicin—uterine cancer	0.000116	0.00733	CcSEcCtD
Podofilox—TOP2A—Circadian rythm related genes—STAR—uterine cancer	0.000115	0.00901	CbGpPWpGaD
Podofilox—Skin exfoliation—Doxorubicin—uterine cancer	0.000107	0.00679	CcSEcCtD
Podofilox—Pruritus—Progesterone—uterine cancer	0.000107	0.00676	CcSEcCtD
Podofilox—Oedema—Dactinomycin—uterine cancer	0.000107	0.00676	CcSEcCtD
Podofilox—TOP2A—Mitotic G1-G1/S phases—RRM2—uterine cancer	0.000103	0.00811	CbGpPWpGaD
Podofilox—NR3C1—lymph node—uterine cancer	0.000103	0.00534	CbGeAlD
Podofilox—TUBA4A—Pathogenic Escherichia coli infection—CTNNB1—uterine cancer	0.000103	0.00807	CbGpPWpGaD
Podofilox—NR3C1—Nuclear Receptor transcription pathway—ESR2—uterine cancer	0.000102	0.00802	CbGpPWpGaD
Podofilox—Dizziness—Progesterone—uterine cancer	0.0001	0.00632	CcSEcCtD
Podofilox—Immune system disorder—Etoposide—uterine cancer	9.84e-05	0.00622	CcSEcCtD
Podofilox—TUBB—Cell Cycle—MLH3—uterine cancer	9.77e-05	0.00767	CbGpPWpGaD
Podofilox—TOP2A—Integrated Pancreatic Cancer Pathway—INHBA—uterine cancer	9.75e-05	0.00765	CbGpPWpGaD
Podofilox—Pruritus—Medroxyprogesterone Acetate—uterine cancer	9.7e-05	0.00613	CcSEcCtD
Podofilox—TOP2A—Gastric Cancer Network 2—CTNNB1—uterine cancer	9.67e-05	0.00759	CbGpPWpGaD
Podofilox—Vomiting—Progesterone—uterine cancer	9.62e-05	0.00608	CcSEcCtD
Podofilox—Rash—Progesterone—uterine cancer	9.54e-05	0.00603	CcSEcCtD
Podofilox—Dermatitis—Progesterone—uterine cancer	9.53e-05	0.00602	CcSEcCtD
Podofilox—Headache—Progesterone—uterine cancer	9.48e-05	0.00599	CcSEcCtD
Podofilox—TOP2A—Circadian rythm related genes—HNF1B—uterine cancer	9.36e-05	0.00735	CbGpPWpGaD
Podofilox—Dermatitis bullous—Epirubicin—uterine cancer	9.23e-05	0.00584	CcSEcCtD
Podofilox—TOP2A—Doxorubicin—Epirubicin—uterine cancer	9.2e-05	0.0819	CbGdCrCtD
Podofilox—TOP2A—Idarubicin—Epirubicin—uterine cancer	9.2e-05	0.0819	CbGdCrCtD
Podofilox—TOP2A—Daunorubicin—Epirubicin—uterine cancer	9.2e-05	0.0819	CbGdCrCtD
Podofilox—Pain—Dactinomycin—uterine cancer	9.14e-05	0.00578	CcSEcCtD
Podofilox—Dizziness—Medroxyprogesterone Acetate—uterine cancer	9.06e-05	0.00573	CcSEcCtD
Podofilox—TUBA4A—Cell Cycle, Mitotic—NDC80—uterine cancer	8.98e-05	0.00705	CbGpPWpGaD
Podofilox—NR3C1—Endoderm Differentiation—EZH2—uterine cancer	8.76e-05	0.00687	CbGpPWpGaD
Podofilox—TUBB—Pathogenic Escherichia coli infection—CTNNB1—uterine cancer	8.74e-05	0.00686	CbGpPWpGaD
Podofilox—Vomiting—Medroxyprogesterone Acetate—uterine cancer	8.71e-05	0.00551	CcSEcCtD
Podofilox—Rash—Medroxyprogesterone Acetate—uterine cancer	8.64e-05	0.00546	CcSEcCtD
Podofilox—Dermatitis—Medroxyprogesterone Acetate—uterine cancer	8.63e-05	0.00546	CcSEcCtD
Podofilox—Headache—Medroxyprogesterone Acetate—uterine cancer	8.59e-05	0.00543	CcSEcCtD
Podofilox—Dermatitis bullous—Doxorubicin—uterine cancer	8.54e-05	0.0054	CcSEcCtD
Podofilox—TOP2A—Epirubicin—Doxorubicin—uterine cancer	8.52e-05	0.0757	CbGdCrCtD
Podofilox—TOP2A—Idarubicin—Doxorubicin—uterine cancer	8.52e-05	0.0757	CbGdCrCtD
Podofilox—TOP2A—Daunorubicin—Doxorubicin—uterine cancer	8.52e-05	0.0757	CbGdCrCtD
Podofilox—TOP2A—Validated transcriptional targets of deltaNp63 isoforms—CDKN2A—uterine cancer	8.29e-05	0.0065	CbGpPWpGaD
Podofilox—TOP2A—Norethindrone—Progesterone—uterine cancer	8.18e-05	0.0728	CbGdCrCtD
Podofilox—NR3C1—Glucocorticoid receptor regulatory network—IRF1—uterine cancer	8.1e-05	0.00636	CbGpPWpGaD
Podofilox—Dry skin—Epirubicin—uterine cancer	8.09e-05	0.00511	CcSEcCtD
Podofilox—TUBA4A—Cell Cycle—NDC80—uterine cancer	8.03e-05	0.00631	CbGpPWpGaD
Podofilox—Unspecified disorder of skin and subcutaneous tissue—Etoposide—uterine cancer	8.02e-05	0.00507	CcSEcCtD
Podofilox—NR3C1—Nuclear Receptors—ESR1—uterine cancer	7.84e-05	0.00616	CbGpPWpGaD
Podofilox—NR3C1—Signaling events mediated by HDAC Class II—ESR1—uterine cancer	7.84e-05	0.00616	CbGpPWpGaD
Podofilox—TUBB—Cell Cycle, Mitotic—NDC80—uterine cancer	7.64e-05	0.006	CbGpPWpGaD
Podofilox—TUBA4A—Cell Cycle, Mitotic—POLD1—uterine cancer	7.64e-05	0.006	CbGpPWpGaD
Podofilox—Skin disorder—Etoposide—uterine cancer	7.52e-05	0.00475	CcSEcCtD
Podofilox—Dry skin—Doxorubicin—uterine cancer	7.48e-05	0.00473	CcSEcCtD
Podofilox—Paraesthesia—Etoposide—uterine cancer	6.95e-05	0.00439	CcSEcCtD
Podofilox—TUBB—Cell Cycle—NDC80—uterine cancer	6.83e-05	0.00536	CbGpPWpGaD
Podofilox—TOP2A—Cell Cycle—MLH3—uterine cancer	6.83e-05	0.00536	CbGpPWpGaD
Podofilox—TUBA4A—Cell Cycle—POLD1—uterine cancer	6.83e-05	0.00536	CbGpPWpGaD
Podofilox—Vomiting—Dactinomycin—uterine cancer	6.8e-05	0.0043	CcSEcCtD
Podofilox—Rash—Dactinomycin—uterine cancer	6.74e-05	0.00426	CcSEcCtD
Podofilox—TUBA4A—Platelet degranulation—VEGFA—uterine cancer	6.71e-05	0.00526	CbGpPWpGaD
Podofilox—CYP2C19—Arachidonic acid metabolism—AKR1C3—uterine cancer	6.66e-05	0.00523	CbGpPWpGaD
Podofilox—Pain—Etoposide—uterine cancer	6.62e-05	0.00418	CcSEcCtD
Podofilox—TOP2A—Levonorgestrel—Progesterone—uterine cancer	6.51e-05	0.0579	CbGdCrCtD
Podofilox—TUBB—Cell Cycle, Mitotic—POLD1—uterine cancer	6.5e-05	0.0051	CbGpPWpGaD
Podofilox—Haematuria—Epirubicin—uterine cancer	6.48e-05	0.0041	CcSEcCtD
Podofilox—TOP2A—Gastric Cancer Network 2—TP53—uterine cancer	6.43e-05	0.00505	CbGpPWpGaD
Podofilox—TUBA4A—Response to elevated platelet cytosolic Ca2+—VEGFA—uterine cancer	6.39e-05	0.00501	CbGpPWpGaD
Podofilox—TUBA4A—Cell Cycle, Mitotic—RRM2—uterine cancer	6.37e-05	0.005	CbGpPWpGaD
Podofilox—TOP2A—Integrated Pancreatic Cancer Pathway—EZH2—uterine cancer	6.25e-05	0.00491	CbGpPWpGaD
Podofilox—TOP2A—Mitotic G1-G1/S phases—CDKN2B—uterine cancer	6.23e-05	0.00489	CbGpPWpGaD
Podofilox—NR3C1—Nuclear Receptor transcription pathway—ESR1—uterine cancer	6.2e-05	0.00486	CbGpPWpGaD
Podofilox—Haemoglobin—Epirubicin—uterine cancer	6.14e-05	0.00388	CcSEcCtD
Podofilox—Haemorrhage—Epirubicin—uterine cancer	6.11e-05	0.00386	CcSEcCtD
Podofilox—CYP2C19—Cytochrome P450 - arranged by substrate type—CYP11A1—uterine cancer	6.1e-05	0.00478	CbGpPWpGaD
Podofilox—NR3C1—Endoderm Differentiation—SMAD3—uterine cancer	6.03e-05	0.00474	CbGpPWpGaD
Podofilox—CYP2C19—Oxidation by Cytochrome P450—CYP11A1—uterine cancer	6.02e-05	0.00472	CbGpPWpGaD
Podofilox—TOP2A—Circadian rythm related genes—EZH2—uterine cancer	6e-05	0.00471	CbGpPWpGaD
Podofilox—Haematuria—Doxorubicin—uterine cancer	6e-05	0.00379	CcSEcCtD
Podofilox—TUBA4A—Metabolism of proteins—INHBA—uterine cancer	5.91e-05	0.00464	CbGpPWpGaD
Podofilox—TUBB—Cell Cycle—POLD1—uterine cancer	5.81e-05	0.00456	CbGpPWpGaD
Podofilox—TOP2A—Integrated Pancreatic Cancer Pathway—ESR2—uterine cancer	5.8e-05	0.00455	CbGpPWpGaD
Podofilox—NR3C1—Regulation of nuclear SMAD2/3 signaling—CDKN2B—uterine cancer	5.75e-05	0.00451	CbGpPWpGaD
Podofilox—TUBA4A—Cell Cycle—RRM2—uterine cancer	5.69e-05	0.00447	CbGpPWpGaD
Podofilox—Haemoglobin—Doxorubicin—uterine cancer	5.68e-05	0.00359	CcSEcCtD
Podofilox—Haemorrhage—Doxorubicin—uterine cancer	5.65e-05	0.00357	CcSEcCtD
Podofilox—TUBA4A—Metabolism of proteins—MME—uterine cancer	5.56e-05	0.00437	CbGpPWpGaD
Podofilox—Immune system disorder—Epirubicin—uterine cancer	5.51e-05	0.00349	CcSEcCtD
Podofilox—NR3C1—Adipogenesis—HMGA1—uterine cancer	5.49e-05	0.00431	CbGpPWpGaD
Podofilox—Pruritus—Etoposide—uterine cancer	5.47e-05	0.00346	CcSEcCtD
Podofilox—TUBB—Cell Cycle, Mitotic—RRM2—uterine cancer	5.42e-05	0.00425	CbGpPWpGaD
Podofilox—TUBA4A—G2/M Transition—EP300—uterine cancer	5.37e-05	0.00422	CbGpPWpGaD
Podofilox—TOP2A—Cell Cycle, Mitotic—NDC80—uterine cancer	5.34e-05	0.00419	CbGpPWpGaD
Podofilox—Erythema—Epirubicin—uterine cancer	5.31e-05	0.00336	CcSEcCtD
Podofilox—TUBA4A—Mitotic G2-G2/M phases—EP300—uterine cancer	5.3e-05	0.00416	CbGpPWpGaD
Podofilox—TOP2A—Integrated Pancreatic Cancer Pathway—STK11—uterine cancer	5.26e-05	0.00413	CbGpPWpGaD
Podofilox—NR3C1—Regulation of nuclear SMAD2/3 signaling—SMAD3—uterine cancer	5.25e-05	0.00412	CbGpPWpGaD
Podofilox—TUBA4A—Hemostasis—IRF1—uterine cancer	5.18e-05	0.00407	CbGpPWpGaD
Podofilox—Dizziness—Etoposide—uterine cancer	5.12e-05	0.00323	CcSEcCtD
Podofilox—TUBA4A—Cell Cycle, Mitotic—YWHAE—uterine cancer	5.11e-05	0.00401	CbGpPWpGaD
Podofilox—Immune system disorder—Doxorubicin—uterine cancer	5.1e-05	0.00322	CcSEcCtD
Podofilox—TUBA4A—Cell Cycle—MLH1—uterine cancer	5.06e-05	0.00397	CbGpPWpGaD
Podofilox—CYP2C19—Phase 1 - Functionalization of compounds—CYP11A1—uterine cancer	4.94e-05	0.00388	CbGpPWpGaD
Podofilox—Vomiting—Etoposide—uterine cancer	4.92e-05	0.00311	CcSEcCtD
Podofilox—Erythema—Doxorubicin—uterine cancer	4.92e-05	0.00311	CcSEcCtD
Podofilox—Rash—Etoposide—uterine cancer	4.88e-05	0.00308	CcSEcCtD
Podofilox—Dermatitis—Etoposide—uterine cancer	4.87e-05	0.00308	CcSEcCtD
Podofilox—Headache—Etoposide—uterine cancer	4.85e-05	0.00306	CcSEcCtD
Podofilox—TUBB—Cell Cycle—RRM2—uterine cancer	4.84e-05	0.0038	CbGpPWpGaD
Podofilox—NR3C1—AP-1 transcription factor network—ESR1—uterine cancer	4.81e-05	0.00378	CbGpPWpGaD
Podofilox—NR3C1—BMAL1:CLOCK,NPAS2 activates circadian gene expression—EP300—uterine cancer	4.78e-05	0.00375	CbGpPWpGaD
Podofilox—TOP2A—Cell Cycle—NDC80—uterine cancer	4.78e-05	0.00375	CbGpPWpGaD
Podofilox—TOP2A—Integrated Pancreatic Cancer Pathway—CDKN2B—uterine cancer	4.72e-05	0.0037	CbGpPWpGaD
Podofilox—CYP2C19—Metapathway biotransformation—AKR1B10—uterine cancer	4.65e-05	0.00365	CbGpPWpGaD
Podofilox—TUBA4A—Cell Cycle—YWHAE—uterine cancer	4.57e-05	0.00359	CbGpPWpGaD
Podofilox—TUBB—G2/M Transition—EP300—uterine cancer	4.57e-05	0.00358	CbGpPWpGaD
Podofilox—TOP2A—Cell Cycle, Mitotic—POLD1—uterine cancer	4.54e-05	0.00357	CbGpPWpGaD
Podofilox—NR3C1—SIDS Susceptibility Pathways—YWHAE—uterine cancer	4.53e-05	0.00355	CbGpPWpGaD
Podofilox—TUBB—Mitotic G2-G2/M phases—EP300—uterine cancer	4.5e-05	0.00353	CbGpPWpGaD
Podofilox—Unspecified disorder of skin and subcutaneous tissue—Epirubicin—uterine cancer	4.49e-05	0.00284	CcSEcCtD
Podofilox—CYP2C19—Cytochrome P450 - arranged by substrate type—CYP19A1—uterine cancer	4.48e-05	0.00352	CbGpPWpGaD
Podofilox—TOP2A—Retinoblastoma (RB) in Cancer—CDKN1B—uterine cancer	4.48e-05	0.00352	CbGpPWpGaD
Podofilox—CYP2C19—Oxidation by Cytochrome P450—CYP19A1—uterine cancer	4.43e-05	0.00347	CbGpPWpGaD
Podofilox—TUBB—Cell Cycle, Mitotic—YWHAE—uterine cancer	4.35e-05	0.00341	CbGpPWpGaD
Podofilox—Oedema—Epirubicin—uterine cancer	4.34e-05	0.00274	CcSEcCtD
Podofilox—CYP2C19—Metapathway biotransformation—AKR1B1—uterine cancer	4.33e-05	0.0034	CbGpPWpGaD
Podofilox—TUBB—Cell Cycle—MLH1—uterine cancer	4.3e-05	0.00337	CbGpPWpGaD
Podofilox—NR3C1—Regulation of nuclear SMAD2/3 signaling—ESR1—uterine cancer	4.28e-05	0.00336	CbGpPWpGaD
Podofilox—NR3C1—AP-1 transcription factor network—CCL2—uterine cancer	4.24e-05	0.00332	CbGpPWpGaD
Podofilox—Skin disorder—Epirubicin—uterine cancer	4.21e-05	0.00266	CcSEcCtD
Podofilox—NR3C1—SIDS Susceptibility Pathways—ESR2—uterine cancer	4.18e-05	0.00328	CbGpPWpGaD
Podofilox—Unspecified disorder of skin and subcutaneous tissue—Doxorubicin—uterine cancer	4.16e-05	0.00263	CcSEcCtD
Podofilox—NR3C1—Adipogenesis—SOCS3—uterine cancer	4.11e-05	0.00323	CbGpPWpGaD
Podofilox—TOP2A—Cell Cycle—POLD1—uterine cancer	4.06e-05	0.00319	CbGpPWpGaD
Podofilox—Oedema—Doxorubicin—uterine cancer	4.01e-05	0.00254	CcSEcCtD
Podofilox—Insomnia—Epirubicin—uterine cancer	3.92e-05	0.00248	CcSEcCtD
Podofilox—Skin disorder—Doxorubicin—uterine cancer	3.9e-05	0.00246	CcSEcCtD
Podofilox—Paraesthesia—Epirubicin—uterine cancer	3.89e-05	0.00246	CcSEcCtD
Podofilox—TUBB—Cell Cycle—YWHAE—uterine cancer	3.89e-05	0.00305	CbGpPWpGaD
Podofilox—TUBA4A—Cell Cycle, Mitotic—CDKN2B—uterine cancer	3.84e-05	0.00302	CbGpPWpGaD
Podofilox—TOP2A—Cell Cycle, Mitotic—RRM2—uterine cancer	3.79e-05	0.00297	CbGpPWpGaD
Podofilox—Pain—Epirubicin—uterine cancer	3.71e-05	0.00234	CcSEcCtD
Podofilox—NR3C1—AP-1 transcription factor network—CDKN2A—uterine cancer	3.69e-05	0.0029	CbGpPWpGaD
Podofilox—CYP3A4—Cytochrome P450 - arranged by substrate type—CYP11A1—uterine cancer	3.67e-05	0.00288	CbGpPWpGaD
Podofilox—TUBA4A—Metabolism of proteins—FBXW7—uterine cancer	3.65e-05	0.00287	CbGpPWpGaD
Podofilox—CYP2C19—Phase 1 - Functionalization of compounds—CYP19A1—uterine cancer	3.64e-05	0.00285	CbGpPWpGaD
Podofilox—Insomnia—Doxorubicin—uterine cancer	3.63e-05	0.00229	CcSEcCtD
Podofilox—CYP3A4—Oxidation by Cytochrome P450—CYP11A1—uterine cancer	3.62e-05	0.00284	CbGpPWpGaD
Podofilox—Paraesthesia—Doxorubicin—uterine cancer	3.6e-05	0.00228	CcSEcCtD
Podofilox—NR3C1—Adipogenesis—SMAD3—uterine cancer	3.59e-05	0.00282	CbGpPWpGaD
Podofilox—NR3C1—Regulation of Androgen receptor activity—EP300—uterine cancer	3.59e-05	0.00282	CbGpPWpGaD
Podofilox—TOP2A—Mitotic G1-G1/S phases—CDKN2A—uterine cancer	3.56e-05	0.0028	CbGpPWpGaD
Podofilox—TOP2A—Integrated Pancreatic Cancer Pathway—ESR1—uterine cancer	3.52e-05	0.00276	CbGpPWpGaD
Podofilox—NR3C1—Circadian Clock—EP300—uterine cancer	3.48e-05	0.00273	CbGpPWpGaD
Podofilox—TUBA4A—Cell Cycle—CDKN2B—uterine cancer	3.43e-05	0.0027	CbGpPWpGaD
Podofilox—Pain—Doxorubicin—uterine cancer	3.43e-05	0.00217	CcSEcCtD
Podofilox—TOP2A—Cell Cycle—RRM2—uterine cancer	3.39e-05	0.00266	CbGpPWpGaD
Podofilox—NR3C1—AP-1 transcription factor network—CXCL8—uterine cancer	3.35e-05	0.00263	CbGpPWpGaD
Podofilox—CYP3A4—Tryptophan metabolism—CYP19A1—uterine cancer	3.34e-05	0.00262	CbGpPWpGaD
Podofilox—TUBA4A—Cell Cycle, Mitotic—BIRC5—uterine cancer	3.32e-05	0.0026	CbGpPWpGaD
Podofilox—NR3C1—AP-1 transcription factor network—CDKN1B—uterine cancer	3.27e-05	0.00257	CbGpPWpGaD
Podofilox—TUBB—Cell Cycle, Mitotic—CDKN2B—uterine cancer	3.27e-05	0.00256	CbGpPWpGaD
Podofilox—CYP2C19—Metapathway biotransformation—AKR1C1—uterine cancer	3.18e-05	0.00249	CbGpPWpGaD
Podofilox—NR3C1—Endoderm Differentiation—CTNNB1—uterine cancer	3.16e-05	0.00248	CbGpPWpGaD
Podofilox—TOP2A—Mitotic G1-G1/S phases—CDKN1B—uterine cancer	3.15e-05	0.00248	CbGpPWpGaD
Podofilox—NR3C1—AP-1 transcription factor network—CTNNB1—uterine cancer	3.09e-05	0.00242	CbGpPWpGaD
Podofilox—Pruritus—Epirubicin—uterine cancer	3.07e-05	0.00194	CcSEcCtD
Podofilox—TOP2A—Cell Cycle, Mitotic—YWHAE—uterine cancer	3.04e-05	0.00239	CbGpPWpGaD
Podofilox—NR3C1—AP-1 transcription factor network—PTEN—uterine cancer	3.01e-05	0.00236	CbGpPWpGaD
Podofilox—TOP2A—Cell Cycle—MLH1—uterine cancer	3.01e-05	0.00236	CbGpPWpGaD
Podofilox—TUBA4A—Platelet activation, signaling and aggregation—VEGFA—uterine cancer	2.97e-05	0.00233	CbGpPWpGaD
Podofilox—CYP3A4—Phase 1 - Functionalization of compounds—CYP11A1—uterine cancer	2.97e-05	0.00233	CbGpPWpGaD
Podofilox—TUBA4A—Cell Cycle—BIRC5—uterine cancer	2.96e-05	0.00233	CbGpPWpGaD
Podofilox—NR3C1—Glucocorticoid receptor regulatory network—CXCL8—uterine cancer	2.95e-05	0.00232	CbGpPWpGaD
Podofilox—TUBB—Cell Cycle—CDKN2B—uterine cancer	2.92e-05	0.00229	CbGpPWpGaD
Podofilox—NR3C1—AP-1 transcription factor network—EP300—uterine cancer	2.87e-05	0.00225	CbGpPWpGaD
Podofilox—Dizziness—Epirubicin—uterine cancer	2.87e-05	0.00181	CcSEcCtD
Podofilox—Pruritus—Doxorubicin—uterine cancer	2.84e-05	0.00179	CcSEcCtD
Podofilox—TUBB—Cell Cycle, Mitotic—BIRC5—uterine cancer	2.82e-05	0.00221	CbGpPWpGaD
Podofilox—TOP2A—Retinoblastoma (RB) in Cancer—TP53—uterine cancer	2.82e-05	0.00221	CbGpPWpGaD
Podofilox—CYP3A4—Metapathway biotransformation—AKR1B10—uterine cancer	2.8e-05	0.0022	CbGpPWpGaD
Podofilox—CYP2C19—Metapathway biotransformation—GPX3—uterine cancer	2.79e-05	0.00219	CbGpPWpGaD
Podofilox—Vomiting—Epirubicin—uterine cancer	2.76e-05	0.00174	CcSEcCtD
Podofilox—Rash—Epirubicin—uterine cancer	2.73e-05	0.00173	CcSEcCtD
Podofilox—Dermatitis—Epirubicin—uterine cancer	2.73e-05	0.00173	CcSEcCtD
Podofilox—NR3C1—Gene Expression—PHF1—uterine cancer	2.72e-05	0.00214	CbGpPWpGaD
Podofilox—TOP2A—Cell Cycle—YWHAE—uterine cancer	2.72e-05	0.00213	CbGpPWpGaD
Podofilox—Headache—Epirubicin—uterine cancer	2.72e-05	0.00172	CcSEcCtD
Podofilox—CYP3A4—Cytochrome P450 - arranged by substrate type—CYP19A1—uterine cancer	2.7e-05	0.00212	CbGpPWpGaD
Podofilox—CYP3A4—Oxidation by Cytochrome P450—CYP19A1—uterine cancer	2.66e-05	0.00209	CbGpPWpGaD
Podofilox—Dizziness—Doxorubicin—uterine cancer	2.65e-05	0.00168	CcSEcCtD
Podofilox—CYP2C19—Biological oxidations—CYP11A1—uterine cancer	2.63e-05	0.00206	CbGpPWpGaD
Podofilox—CYP3A4—Metapathway biotransformation—AKR1B1—uterine cancer	2.6e-05	0.00204	CbGpPWpGaD
Podofilox—CYP2C19—Metapathway biotransformation—CYP11A1—uterine cancer	2.59e-05	0.00203	CbGpPWpGaD
Podofilox—TOP2A—Integrated Pancreatic Cancer Pathway—ERBB2—uterine cancer	2.58e-05	0.00203	CbGpPWpGaD
Podofilox—NR3C1—Regulation of nuclear SMAD2/3 signaling—EP300—uterine cancer	2.56e-05	0.00201	CbGpPWpGaD
Podofilox—Vomiting—Doxorubicin—uterine cancer	2.55e-05	0.00161	CcSEcCtD
Podofilox—Rash—Doxorubicin—uterine cancer	2.53e-05	0.0016	CcSEcCtD
Podofilox—NR3C1—Glucocorticoid receptor regulatory network—EP300—uterine cancer	2.53e-05	0.00199	CbGpPWpGaD
Podofilox—Dermatitis—Doxorubicin—uterine cancer	2.53e-05	0.0016	CcSEcCtD
Podofilox—TUBB—Cell Cycle—BIRC5—uterine cancer	2.52e-05	0.00198	CbGpPWpGaD
Podofilox—NR3C1—FOXA2 and FOXA3 transcription factor networks—AKT1—uterine cancer	2.52e-05	0.00197	CbGpPWpGaD
Podofilox—Headache—Doxorubicin—uterine cancer	2.51e-05	0.00159	CcSEcCtD
Podofilox—CYP2C19—Metapathway biotransformation—AKR1C3—uterine cancer	2.44e-05	0.00192	CbGpPWpGaD
Podofilox—TOP2A—Integrated Pancreatic Cancer Pathway—CDKN1B—uterine cancer	2.39e-05	0.00188	CbGpPWpGaD
Podofilox—CYP2C19—Metabolism of lipids and lipoproteins—SRD5A2—uterine cancer	2.33e-05	0.00183	CbGpPWpGaD
Podofilox—TUBA4A—Platelet activation, signaling and aggregation—PIK3CA—uterine cancer	2.32e-05	0.00182	CbGpPWpGaD
Podofilox—NR3C1—Gene Expression—CHD4—uterine cancer	2.31e-05	0.00182	CbGpPWpGaD
Podofilox—TOP2A—Cell Cycle, Mitotic—CDKN2B—uterine cancer	2.28e-05	0.00179	CbGpPWpGaD
Podofilox—TOP2A—Integrated Pancreatic Cancer Pathway—CTNNB1—uterine cancer	2.26e-05	0.00177	CbGpPWpGaD
Podofilox—TOP2A—Integrated Pancreatic Cancer Pathway—PTEN—uterine cancer	2.2e-05	0.00173	CbGpPWpGaD
Podofilox—TUBA4A—Cell Cycle, Mitotic—CDKN2A—uterine cancer	2.2e-05	0.00172	CbGpPWpGaD
Podofilox—CYP3A4—Phase 1 - Functionalization of compounds—CYP19A1—uterine cancer	2.19e-05	0.00172	CbGpPWpGaD
Podofilox—TOP2A—Circadian rythm related genes—PTEN—uterine cancer	2.11e-05	0.00166	CbGpPWpGaD
Podofilox—TOP2A—Integrated Pancreatic Cancer Pathway—EP300—uterine cancer	2.1e-05	0.00165	CbGpPWpGaD
Podofilox—NR3C1—AP-1 transcription factor network—TP53—uterine cancer	2.05e-05	0.00161	CbGpPWpGaD
Podofilox—TOP2A—Cell Cycle—CDKN2B—uterine cancer	2.04e-05	0.0016	CbGpPWpGaD
Podofilox—TOP2A—Circadian rythm related genes—EP300—uterine cancer	2.01e-05	0.00158	CbGpPWpGaD
Podofilox—NR3C1—Generic Transcription Pathway—PGR—uterine cancer	2e-05	0.00157	CbGpPWpGaD
Podofilox—TOP2A—Integrated Pancreatic Cancer Pathway—VEGFA—uterine cancer	1.99e-05	0.00156	CbGpPWpGaD
Podofilox—TOP2A—Cell Cycle, Mitotic—BIRC5—uterine cancer	1.97e-05	0.00155	CbGpPWpGaD
Podofilox—TUBA4A—Cell Cycle—CDKN2A—uterine cancer	1.96e-05	0.00154	CbGpPWpGaD
Podofilox—TUBA4A—Cell Cycle, Mitotic—CDKN1B—uterine cancer	1.95e-05	0.00153	CbGpPWpGaD
Podofilox—NR3C1—Gene Expression—SUZ12—uterine cancer	1.94e-05	0.00152	CbGpPWpGaD
Podofilox—CYP2C19—Biological oxidations—CYP19A1—uterine cancer	1.93e-05	0.00152	CbGpPWpGaD
Podofilox—CYP3A4—Metapathway biotransformation—AKR1C1—uterine cancer	1.91e-05	0.0015	CbGpPWpGaD
Podofilox—CYP2C19—Metapathway biotransformation—CYP19A1—uterine cancer	1.9e-05	0.0015	CbGpPWpGaD
Podofilox—TUBA4A—Platelet activation, signaling and aggregation—AKT1—uterine cancer	1.9e-05	0.00149	CbGpPWpGaD
Podofilox—NR3C1—Adipogenesis—CTNNB1—uterine cancer	1.88e-05	0.00148	CbGpPWpGaD
Podofilox—TUBA4A—Metabolism of proteins—CCL2—uterine cancer	1.88e-05	0.00147	CbGpPWpGaD
Podofilox—TUBB—Cell Cycle, Mitotic—CDKN2A—uterine cancer	1.87e-05	0.00147	CbGpPWpGaD
Podofilox—NR3C1—Glucocorticoid receptor regulatory network—TP53—uterine cancer	1.81e-05	0.00142	CbGpPWpGaD
Podofilox—NR3C1—Generic Transcription Pathway—ESR2—uterine cancer	1.77e-05	0.00139	CbGpPWpGaD
Podofilox—NR3C1—SIDS Susceptibility Pathways—CXCL8—uterine cancer	1.76e-05	0.00138	CbGpPWpGaD
Podofilox—TOP2A—Cell Cycle—BIRC5—uterine cancer	1.76e-05	0.00138	CbGpPWpGaD
Podofilox—TUBA4A—Cell Cycle—CDKN1B—uterine cancer	1.74e-05	0.00137	CbGpPWpGaD
Podofilox—TUBA4A—Cell Cycle, Mitotic—EP300—uterine cancer	1.71e-05	0.00134	CbGpPWpGaD
Podofilox—TOP2A—Integrated Pancreatic Cancer Pathway—KRAS—uterine cancer	1.69e-05	0.00133	CbGpPWpGaD
Podofilox—CYP2C19—Metabolism of lipids and lipoproteins—AKR1B1—uterine cancer	1.68e-05	0.00132	CbGpPWpGaD
Podofilox—CYP2C19—Metabolism of lipids and lipoproteins—STAR—uterine cancer	1.68e-05	0.00132	CbGpPWpGaD
Podofilox—CYP3A4—Metapathway biotransformation—GPX3—uterine cancer	1.68e-05	0.00132	CbGpPWpGaD
Podofilox—TUBB—Cell Cycle—CDKN2A—uterine cancer	1.67e-05	0.00131	CbGpPWpGaD
Podofilox—TUBB—Cell Cycle, Mitotic—CDKN1B—uterine cancer	1.65e-05	0.0013	CbGpPWpGaD
Podofilox—NR3C1—SIDS Susceptibility Pathways—CTNNB1—uterine cancer	1.63e-05	0.00128	CbGpPWpGaD
Podofilox—TUBA4A—Hemostasis—EP300—uterine cancer	1.62e-05	0.00127	CbGpPWpGaD
Podofilox—CYP3A4—Biological oxidations—CYP11A1—uterine cancer	1.58e-05	0.00124	CbGpPWpGaD
Podofilox—CYP3A4—Metapathway biotransformation—CYP11A1—uterine cancer	1.56e-05	0.00122	CbGpPWpGaD
Podofilox—TOP2A—Integrated Pancreatic Cancer Pathway—PIK3CA—uterine cancer	1.55e-05	0.00122	CbGpPWpGaD
Podofilox—NR3C1—Regulation of nuclear SMAD2/3 signaling—AKT1—uterine cancer	1.54e-05	0.00121	CbGpPWpGaD
Podofilox—TUBA4A—Hemostasis—VEGFA—uterine cancer	1.53e-05	0.0012	CbGpPWpGaD
Podofilox—NR3C1—Glucocorticoid receptor regulatory network—AKT1—uterine cancer	1.53e-05	0.0012	CbGpPWpGaD
Podofilox—TUBA4A—Cell Cycle—EP300—uterine cancer	1.53e-05	0.0012	CbGpPWpGaD
Podofilox—TUBA4A—Hemostasis—NRAS—uterine cancer	1.51e-05	0.00119	CbGpPWpGaD
Podofilox—NR3C1—SIDS Susceptibility Pathways—EP300—uterine cancer	1.51e-05	0.00119	CbGpPWpGaD
Podofilox—TOP2A—Integrated Pancreatic Cancer Pathway—TP53—uterine cancer	1.5e-05	0.00118	CbGpPWpGaD
Podofilox—TUBA4A—Metabolism of proteins—CXCL8—uterine cancer	1.48e-05	0.00117	CbGpPWpGaD
Podofilox—TUBB—Cell Cycle—CDKN1B—uterine cancer	1.48e-05	0.00116	CbGpPWpGaD
Podofilox—CYP3A4—Metapathway biotransformation—AKR1C3—uterine cancer	1.47e-05	0.00115	CbGpPWpGaD
Podofilox—TUBB—Cell Cycle, Mitotic—EP300—uterine cancer	1.45e-05	0.00114	CbGpPWpGaD
Podofilox—TOP2A—Circadian rythm related genes—TP53—uterine cancer	1.44e-05	0.00113	CbGpPWpGaD
Podofilox—NR3C1—Generic Transcription Pathway—CDKN2B—uterine cancer	1.44e-05	0.00113	CbGpPWpGaD
Podofilox—NR3C1—SIDS Susceptibility Pathways—VEGFA—uterine cancer	1.43e-05	0.00112	CbGpPWpGaD
Podofilox—TUBA4A—Metabolism of proteins—CTNNB1—uterine cancer	1.37e-05	0.00108	CbGpPWpGaD
Podofilox—NR3C1—Generic Transcription Pathway—SMAD3—uterine cancer	1.31e-05	0.00103	CbGpPWpGaD
Podofilox—TOP2A—Cell Cycle, Mitotic—CDKN2A—uterine cancer	1.31e-05	0.00103	CbGpPWpGaD
Podofilox—TUBA4A—Hemostasis—KRAS—uterine cancer	1.3e-05	0.00102	CbGpPWpGaD
Podofilox—TUBB—Cell Cycle—EP300—uterine cancer	1.3e-05	0.00102	CbGpPWpGaD
Podofilox—TOP2A—Integrated Pancreatic Cancer Pathway—AKT1—uterine cancer	1.27e-05	0.000996	CbGpPWpGaD
Podofilox—CYP2C19—Metabolism of lipids and lipoproteins—AKR1C1—uterine cancer	1.24e-05	0.000971	CbGpPWpGaD
Podofilox—TUBA4A—Hemostasis—PIK3CA—uterine cancer	1.2e-05	0.00094	CbGpPWpGaD
Podofilox—TOP2A—Cell Cycle—CDKN2A—uterine cancer	1.17e-05	0.000917	CbGpPWpGaD
Podofilox—CYP3A4—Biological oxidations—CYP19A1—uterine cancer	1.16e-05	0.000912	CbGpPWpGaD
Podofilox—TUBA4A—Hemostasis—TP53—uterine cancer	1.16e-05	0.000909	CbGpPWpGaD
Podofilox—TOP2A—Cell Cycle, Mitotic—CDKN1B—uterine cancer	1.16e-05	0.000908	CbGpPWpGaD
Podofilox—CYP3A4—Metapathway biotransformation—CYP19A1—uterine cancer	1.15e-05	0.000899	CbGpPWpGaD
Podofilox—TUBA4A—Hemostasis—HRAS—uterine cancer	1.11e-05	0.00087	CbGpPWpGaD
Podofilox—TUBA4A—Cell Cycle—TP53—uterine cancer	1.09e-05	0.000858	CbGpPWpGaD
Podofilox—NR3C1—Generic Transcription Pathway—ESR1—uterine cancer	1.07e-05	0.00084	CbGpPWpGaD
Podofilox—CYP2C19—Metabolism—SRD5A2—uterine cancer	1.04e-05	0.000815	CbGpPWpGaD
Podofilox—CYP2C19—Metabolism—NDUFB11—uterine cancer	1.04e-05	0.000815	CbGpPWpGaD
Podofilox—TOP2A—Cell Cycle—CDKN1B—uterine cancer	1.03e-05	0.000812	CbGpPWpGaD
Podofilox—TOP2A—Cell Cycle, Mitotic—EP300—uterine cancer	1.02e-05	0.000798	CbGpPWpGaD
Podofilox—CYP2C19—Metabolism of lipids and lipoproteins—CYP11A1—uterine cancer	1.01e-05	0.000791	CbGpPWpGaD
Podofilox—TUBA4A—Hemostasis—AKT1—uterine cancer	9.78e-06	0.000768	CbGpPWpGaD
Podofilox—NR3C1—Gene Expression—PGR—uterine cancer	9.65e-06	0.000758	CbGpPWpGaD
Podofilox—CYP2C19—Metabolism of lipids and lipoproteins—AKR1C3—uterine cancer	9.52e-06	0.000747	CbGpPWpGaD
Podofilox—TUBB—Cell Cycle—TP53—uterine cancer	9.3e-06	0.00073	CbGpPWpGaD
Podofilox—NR3C1—Gene Expression—EZH2—uterine cancer	9.17e-06	0.00072	CbGpPWpGaD
Podofilox—TOP2A—Cell Cycle—EP300—uterine cancer	9.08e-06	0.000713	CbGpPWpGaD
Podofilox—NR3C1—Gene Expression—ESR2—uterine cancer	8.5e-06	0.000667	CbGpPWpGaD
Podofilox—CYP2C19—Metabolism—STAR—uterine cancer	7.5e-06	0.000589	CbGpPWpGaD
Podofilox—CYP2C19—Metabolism—AKR1B1—uterine cancer	7.5e-06	0.000589	CbGpPWpGaD
Podofilox—CYP2C19—Metabolism of lipids and lipoproteins—CYP19A1—uterine cancer	7.42e-06	0.000582	CbGpPWpGaD
Podofilox—NR3C1—Gene Expression—CDKN2B—uterine cancer	6.92e-06	0.000543	CbGpPWpGaD
Podofilox—TOP2A—Cell Cycle—TP53—uterine cancer	6.5e-06	0.00051	CbGpPWpGaD
Podofilox—NR3C1—Gene Expression—SMAD3—uterine cancer	6.32e-06	0.000496	CbGpPWpGaD
Podofilox—CYP3A4—Metabolism—SRD5A2—uterine cancer	6.24e-06	0.00049	CbGpPWpGaD
Podofilox—CYP3A4—Metabolism—NDUFB11—uterine cancer	6.24e-06	0.00049	CbGpPWpGaD
Podofilox—CYP2C19—Metabolism—POLD1—uterine cancer	5.89e-06	0.000462	CbGpPWpGaD
Podofilox—CYP2C19—Metabolism—AKR1C1—uterine cancer	5.51e-06	0.000432	CbGpPWpGaD
Podofilox—NR3C1—Gene Expression—ESR1—uterine cancer	5.15e-06	0.000405	CbGpPWpGaD
Podofilox—CYP2C19—Metabolism—RRM2—uterine cancer	4.91e-06	0.000385	CbGpPWpGaD
Podofilox—CYP2C19—Metabolism—DCN—uterine cancer	4.76e-06	0.000374	CbGpPWpGaD
Podofilox—CYP3A4—Metabolism—STAR—uterine cancer	4.51e-06	0.000354	CbGpPWpGaD
Podofilox—CYP3A4—Metabolism—AKR1B1—uterine cancer	4.51e-06	0.000354	CbGpPWpGaD
Podofilox—CYP2C19—Metabolism—CYP11A1—uterine cancer	4.49e-06	0.000352	CbGpPWpGaD
Podofilox—CYP2C19—Metabolism—AKR1C3—uterine cancer	4.24e-06	0.000333	CbGpPWpGaD
Podofilox—CYP3A4—Metabolism—POLD1—uterine cancer	3.54e-06	0.000278	CbGpPWpGaD
Podofilox—CYP3A4—Metabolism—AKR1C1—uterine cancer	3.31e-06	0.00026	CbGpPWpGaD
Podofilox—CYP2C19—Metabolism—STK11—uterine cancer	3.3e-06	0.000259	CbGpPWpGaD
Podofilox—CYP2C19—Metabolism—CYP19A1—uterine cancer	3.3e-06	0.000259	CbGpPWpGaD
Podofilox—CYP2C19—Metabolism of lipids and lipoproteins—PTEN—uterine cancer	3.1e-06	0.000243	CbGpPWpGaD
Podofilox—CYP2C19—Metabolism of lipids and lipoproteins—EP300—uterine cancer	2.96e-06	0.000232	CbGpPWpGaD
Podofilox—CYP3A4—Metabolism—RRM2—uterine cancer	2.95e-06	0.000232	CbGpPWpGaD
Podofilox—CYP3A4—Metabolism—DCN—uterine cancer	2.87e-06	0.000225	CbGpPWpGaD
Podofilox—CYP3A4—Metabolism—CYP11A1—uterine cancer	2.7e-06	0.000212	CbGpPWpGaD
Podofilox—CYP3A4—Metabolism—AKR1C3—uterine cancer	2.55e-06	0.0002	CbGpPWpGaD
Podofilox—CYP2C19—Metabolism—MTHFR—uterine cancer	2.48e-06	0.000195	CbGpPWpGaD
Podofilox—CYP2C19—Metabolism of lipids and lipoproteins—PIK3CA—uterine cancer	2.19e-06	0.000172	CbGpPWpGaD
Podofilox—CYP3A4—Metabolism—STK11—uterine cancer	1.99e-06	0.000156	CbGpPWpGaD
Podofilox—CYP3A4—Metabolism—CYP19A1—uterine cancer	1.99e-06	0.000156	CbGpPWpGaD
Podofilox—NR3C1—Gene Expression—AKT1—uterine cancer	1.86e-06	0.000146	CbGpPWpGaD
Podofilox—CYP3A4—Metabolism—MTHFR—uterine cancer	1.49e-06	0.000117	CbGpPWpGaD
Podofilox—CYP2C19—Metabolism—PTEN—uterine cancer	1.38e-06	0.000108	CbGpPWpGaD
Podofilox—CYP2C19—Metabolism—EP300—uterine cancer	1.32e-06	0.000103	CbGpPWpGaD
Podofilox—CYP2C19—Metabolism—PIK3CA—uterine cancer	9.74e-07	7.65e-05	CbGpPWpGaD
Podofilox—CYP3A4—Metabolism—PTEN—uterine cancer	8.3e-07	6.52e-05	CbGpPWpGaD
Podofilox—CYP2C19—Metabolism—AKT1—uterine cancer	7.96e-07	6.25e-05	CbGpPWpGaD
Podofilox—CYP3A4—Metabolism—EP300—uterine cancer	7.92e-07	6.22e-05	CbGpPWpGaD
Podofilox—CYP3A4—Metabolism—PIK3CA—uterine cancer	5.86e-07	4.6e-05	CbGpPWpGaD
Podofilox—CYP3A4—Metabolism—AKT1—uterine cancer	4.78e-07	3.76e-05	CbGpPWpGaD
